Clinical Trial: A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06794268) titled 'A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting' on Jan. 20.

Brief Summary: The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

Study Start Date: Feb. 04

Study Type: OBSERVATIONAL

Condition: Follicular Lymphoma

Intervention: BIOLOGICAL: Lisocabtagene maraleucel

As per product label

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Juno T...